Trials that use: P-values
New to this method? Read the tutorial →
20,601 results
- NIMBLeIndependent statistical analysis of Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- NIMBLEIndependent statistical analysis of Novel Methods for Implementing Measurement-Based Care for Youth in Low-resource Environments: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- NIMBUSIndependent statistical analysis of A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple…
- NIMBUSIndependent statistical analysis of A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of AZD5069 in Patients With Uncontrolled Persistent Asthma.: primary endpoint results, effect estimate with confidence interval, sample-size…
- Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV: Complete Statistical AnalysisIndependent statistical analysis of Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- NINJA NGALIndependent statistical analysis of Assessment of Urinary NGAL to Predict AKI in Children Receiving Multiple Nephrotoxic Medications: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1): Complete Statistical AnalysisIndependent statistical analysis of Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC): Complete Statistical AnalysisIndependent statistical analysis of Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02389764).
- Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors: Complete Statistical AnalysisIndependent statistical analysis of Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Ninvasive Cardiac Output Measurements During Cesarean Delivery Under Spinal Anesthesia.: Complete Statistical AnalysisIndependent statistical analysis of Ninvasive Cardiac Output Measurements During Cesarean Delivery Under Spinal Anesthesia.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01928797).
- NIPUTFDIndependent statistical analysis of Neuroimaging in Patients Undergoing TMS for Depression: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02974296).
- NIR-FlowIndependent statistical analysis of Transcranial Near-Infrared Light in Healthy Subjects: a Cerebral Blood Flow Study With Diffuse Correlation Spectroscopy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- NIRAFIndependent statistical analysis of Evaluating Impact of NIRAF Detection for Identifying Parathyroid Glands During Parathyroidectomy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Niraparib + Dostarlimab + RT in Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Niraparib + Dostarlimab + RT in Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04409002).
- Niraparib + Dostarlimab In BRCA Mutated Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Niraparib + Dostarlimab In BRCA Mutated Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04584255).
- Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- NIRVANAIndependent statistical analysis of A Study to Learn About How Elinzanetant Works and How Safe it is in Women Having Sleep Disturbances Associated With Menopause: primary endpoint results, effect estimate with confidence…
- NIRVANAIndependent statistical analysis of Validation of Molecular Diagnostic Thecnologies for Lung Cancer Patients.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03220230).
- NIRVANAIndependent statistical analysis of Nicotinamide Riboside in SARS-CoV-2 (COVID-19) Patients for Renal Protection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04818216).
- NIRVANAIndependent statistical analysis of Study to Evaluate Effect of Nebivolol on Angina in Women With Microvascular Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Nitrate Supplementation and Exercise Tolerance in Patients With Type 2 Diabetes: Complete Statistical AnalysisIndependent statistical analysis of Nitrate Supplementation and Exercise Tolerance in Patients With Type 2 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Nitric Oxide Releasing Solution (NORS) Footbath to Treat Athlete’s Foot: Complete Statistical AnalysisIndependent statistical analysis of Nitric Oxide Releasing Solution (NORS) Footbath to Treat Athlete's Foot: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02871011).
- Nitrite Infusion in Islet Cell Transplantation: Complete Statistical AnalysisIndependent statistical analysis of Nitrite Infusion in Islet Cell Transplantation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03544242).
- Nitroglycerin Infusion During Cardiac Surgery: Complete Statistical AnalysisIndependent statistical analysis of Nitroglycerin Infusion During Cardiac Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01901419).
- Nitrous Oxide for External Cephalic Version: Complete Statistical AnalysisIndependent statistical analysis of Nitrous Oxide for External Cephalic Version: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03502915).
- Nitrous Oxide for Identifying the Intersegmental Plane in Segmentectomy: A Randomized Controlled Trial: Complete Statistical AnalysisIndependent statistical analysis of Nitrous Oxide for Identifying the Intersegmental Plane in Segmentectomy: A Randomized Controlled Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Nitrous Oxide Induction Induces Amnesia in Pediatric Patients: Complete Statistical AnalysisIndependent statistical analysis of Nitrous Oxide Induction Induces Amnesia in Pediatric Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02050152).
- Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers: primary endpoint results, effect estimate…
- Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016): Complete Statistical AnalysisIndependent statistical analysis of Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016): primary endpoint results, effect estimate with confidence interval,…
- Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03693846).
- Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03055013).
- Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size…
- Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- NK-VS-MMIndependent statistical analysis of Clinical Trial of Expanded and Activated Autologous NK Cells to Treat Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…